SAN DIEGO, May 24, 2022 /PRNewswire/ Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery, today announced
CT pushes for prescription drug price control
Julia Bergman
FacebookTwitterEmail
Connecticut and Massachusetts worked together early in the coronavirus pandemic to institute similar restrictions to keep their residents safe, and later to reopen their economies and lift stay-at-home orders.
Now, Govs. Ned Lamont and Charlie Baker are hoping to lead the country in addressing one of the major underlying costs of health care: prescription drug prices.
The governors hosted a joint news conference Tuesday to discuss similar legislation they have proposed in their states, which, they said, would protect consumers and hold drug manufacturers accountable.
Lamont’s two-year budget plan proposes capping annual increases in the cost of prescription drugs. Under the governor’s proposal, yearly hikes would be limited to the rate of inflation plus 2 percent. Drug manufacturers that exceed that amount would be fined, and that money would in turn be used to support subsidies for health cove
Opinion: How a CT prescription drug bill would impair research
Paige Mahaney, Ph.D.
FacebookTwitterEmail
Boehringer Ingelheim’s U.S. headquarters in Ridgefield, Connecticut.Contributed photo
I lead Boehringer Ingelheim’s research team in Connecticut, and every day I witness our dedicated scientists striving to discover breakthrough treatments for patients. Our mission compels me to express Boehringer Ingelheim’s opposition to Gov. Ned Lamont’s proposal to set government price controls on prescription drugs (contained in House Bill 6447). The governor’s proposal will not help patients but instead, will hurt the ability of companies like ours to stay focused and invest in research to advance innovative new therapies.